Zogenix Resubmits New Drug Application

Zogenix, Inc. recently announced that it has resubmitted its New Drug Application (NDA) for FINTEPLA® (ZX008, fenfluramine) for the treatment of seizures associated with Dravet syndrome to the U.S. Food and Drug Administration (FDA). The NDA is based on data from two pivotal Phase 3 trials and an interim analysis from an ongoing open label extension study.

For updates and more information, visit Zogenix’s website here.